Study Finds Handheld Far UV-C Devices Effectively Reduce Surface Pathogens in a Healthcare Setting

Portable germicidal light technology disinfects high-touch clinical surfaces in seconds

DETROIT–(BUSINESS WIRE)–Freestyle Partners, LLC announced today the results of an in-hospital disinfection study using first-of-its-kind handheld Filtered Far UV-C devices to demonstrate the effective, rapid reduction of healthcare-acquired infection-causing pathogens from certain high-touch clinical surfaces. The study may help to address a major in-hospital challenge of disinfecting high-touch clinical surfaces that often cannot be disinfected by traditional manual methods.


Reducing healthcare-acquired infections (HAIs) is an ongoing and critical need within the global healthcare network. In U.S. healthcare facilities alone, 1.7 million patients contract HAIs annually and HAIs cause 99,000 deaths every year. Surface pathogens can persist for days to months and studies show that 50% of surfaces in healthcare environments do not receive adequate levels of disinfection during manual chemical cleaning. Yearly expenses for the U.S. healthcare system to combat HAIs are estimated between $28-$33 billion.

The study, led by researchers at The University of Texas MD Anderson Cancer Center, showed a statistically significant reduction of surface pathogens known to cause HAIs with the use of the Freestyle Partners handheld Filtered Far UV-C devices on most surfaces tested in clinical work areas of hematologic malignancy and stem cell units in and around patient care areas.

The device has proven effective in preclinical and clinical studies and offers the advantage of ‘no-touch’ disinfection when manual methods are not optimal. The results of the efficacy study work have been accepted and will be presented at several global infectious disease conferences including The Society for Healthcare Epidemiology of America (SHEA), The European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) and The International Immunocompromised Host Society (ICHS).

This study continued to validate the highly effective and rapid reduction of harmful pathogens on most high touch surfaces. The devices used implemented patented functionality that enables proper use and achieved desired efficacy.

Filtered Far UV-C is a human-safe, breakthrough disinfection technology that utilizes invisible germicidal light to kill pathogens – viruses, bacteria, spores, fungi – and works in seconds when used in a handheld format, without 2–10-minute wet dwell times required by chemical disinfectants to achieve necessary efficacy.

“This study provides further real-world data on the efficacy of handheld Filtered Far UV-C devices to reduce surface pathogens which we hope could ultimately improve patient care and tackle the tremendous expenses healthcare institutions face in fighting HAIs,” said Jennifer Rosen, co-founder of Freestyle Partners, LLC.

Freestyle Partners, LLC has worked with scientists, technologists, and engineers within the Filtered Far UV-C space to develop prototypes, conduct lab testing, and publish peer-reviewed research on both the efficacy and safety of handheld Filtered Far UV-C devices.

For more evidence-based and peer-reviewed papers in scientific journals that support the efficacy, safety and use of Filtered Far UV-C, visit: freestylepartnersllc.com/the-science

About Freestyle Partners, LLC

Based in Detroit, Freestyle Partners, LLC seeks to help people across the world live healthier lives by reducing harmful and deadly pathogens on surfaces and in shared air through the efficacious and safe application of the breakthrough disinfection technology including applications within the handheld, in-vehicle, transportation (airplanes, automobiles, buses, trains, ships, etc.) and autonomous segments, Filtered Far UV-C. For more information, visit www.freestylepartnersllc.com.

Contacts

Marybeth Roberts

Tilis Group

1-951-553-3343

[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.